Article Sidebar

pdf
Date Published: 30/08/2023
Abstract Views: 108
Views pdf: 95
DOI: https://doi.org/10.51298/vmj.v529i1B.6369
Issue
Vol. 529 No. 1B (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. N., Nguyễn, T. H., Thái, T. N., & Lê, V. T. (2023). SURVEY CHANGES OF PLASMA TNF - ALPHA, INTERLEUKIN 6 LEVELS IN PATIENTS WITH LUPUS NEPHRITIS BEFORE AND AFTER 6 MONTHS OF TREATMENT. Vietnam Medical Journal, 529(1B). https://doi.org/10.51298/vmj.v529i1B.6369

SURVEY CHANGES OF PLASMA TNF - ALPHA, INTERLEUKIN 6 LEVELS IN PATIENTS WITH LUPUS NEPHRITIS BEFORE AND AFTER 6 MONTHS OF TREATMENT

Thị Ngọc Nguyễn1,2,, Thu Hương Nguyễn2, Thiên Nam Thái2, Việt Thắng Lê1
1 Vietnam Military Medical Academy
2 Vietnam National Children's Hospital.

Main Article Content

Abstract

Objectives: To Investigate changes in plasma TNF-alpha, IL-6 levels and its relationship with renal response in pediatric lupus nephritis before and after 6 months of treatment. Patients and Methods: Prospective description compared with the healthy children group, longitudinal follow-up of 75 patients (45 children with lupus nephritis with longitudinal follow-up after 6 months of treatment and 30 healthy children) from 9/2019 to 9/2022 at National Children's Hospital. Results: Plasma TNF-alpha, IL-6 levels after treatment were lower than before treatment, plasma TNF-alpha levels were not different from the control group, p > 0.05. The level of plasma IL-6 after treatment was lower than before, but still higher than the control group, p<0.001. The levels of TNF-alpha, IL-6 have predictive values ​​in pediatric lupus nephritis who do not renal response, with AUC: 0.764; 0.901, p< 0.001. Conclusion: The plasma levels of TNF alpha and IL6 after treatment decrease but do not return to normal completely, but can predict no renal response in patients with lupus nephritis.

Article Details

Keywords

Lupus nephritis, The plasma TNF-alpha, IL-6. predicting the outcome of treatment

References

1. Bùi Song Hương (2019), Nghiên cứu mối liên quan giữa kháng thể nucleosome và C1q với mức độ hoạt động bệnh và tổn thương thận trong Lupus ban đỏ hệ thống ở trẻ em, Luận án tiến sỹ Y học chuyên ngành Nhi Khoa, Đại học Y Hà nội.
2. Thái Thiên Nam (2010). Bệnh lupus ban đỏ hệ thống tại Bệnh viện Nhi Trung ương: Đặc điểm lâm sàng, hình ảnh tổn thương mô bệnh học và đánh giá kết quả điều trị ban đầu. Thông tin Y dược, 8, 18-22.8.
3. Abdel Galil SM, Ezzeldin N, El-Boshy ME (2015). The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine; 76: 280–287.
4. Aringer M, Zimmermann C, Graninger WB, et al (2002). TNF-α is an essential mediator in lupus nephritis. Arthritis Rheum; 46:3418-9.
5. Davidson JE, Fu Q, Ji B, Rao S, Roth D, Magder LS et al (2018) Renal remission status and long-term renal survival in patients with lupus nephritis: a retrospective cohort analysis. J Rheumatol 45(5):671–677.
6. Nezhad ST and Sepaskhah R (2008). Correlation of clinical and pathological findings in patients with lupus nephritis: a five-year experience in Iran. Saudi J Kidney Dis Transpl, 19(1), 32-40.
7. Tackey E, Lipsky PE, Illei GG (2004). The rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus; 13: 339–343.
8. Umare V, Pradhan V, Nadkar M, Rajadhyaksha A, Patwardhan M, Ghosh KK, et al (2014). Effect of proinflammatory cytokines (IL-6, TNF-α, and IL-1β) on clinical manifestations in Indian SLE patients. Mediators Inflamm.